

Second Edition

Integrated **Pharmaceuticals**

**Applied Preformulation, Product Design,
and Regulatory Science**

Antoine Al-Achi

Mali Ram Gupta

William Craig Stagner



WILEY

Integrated Pharmaceuticals

Integrated Pharmaceutics

Applied Preformulation, Product Design, and Regulatory Science

Second Edition

Antoine Al-Achi
Campbell University
North Carolina, USA

Mali Ram Gupta
Campbell University
North Carolina, USA

William Craig Stagner
Campbell University
North Carolina, USA

WILEY

This edition first published 2023
© 2023 John Wiley & Sons, Inc.

Edition History

John Wiley & Sons, Inc. (1e, 2013)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Antoine Al-Achi, Mali Ram Gupta, and William Craig Stagner to be identified as the authors of this work has been asserted in accordance with law.

Registered Office(s)

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data applied for:

Harback ISBN: 9781119574699

Cover Design and Image: Wiley

Set in 9.5/12.5pt STIXTwoText by Straive, Pondicherry, India

*To my wife, Pamela Cardella Al-Achi, and my sons, Elias Gabriel, Anthony William, and John Peter.
To my beloved father and mother, Elias and René Nassif Tadros. To my siblings and their families,
Peter Al-Achi, Claudette Martone, and Kamil Al Achi.*

To my wife, Sulochna Gupta, and my children and grandchildren, Michael, Saijal, Deepak, Yolanda, Nathan, Maya, and Diago. To my beloved father, Harchand Rai, my mother, Anachi, and the entire Mittal family.

To my wife Nancy, and our children and grandchildren, Ryan, Beth, Ethan; Tripp, Kelly, Amelia; and Justin, Lauren, Henry, Hudson.

To all our students: past, present, and future.

Contents

Foreword to Second Edition	<i>xv</i>
Foreword to First Edition	<i>xvi</i>
Preface to Second Edition	<i>xvii</i>
Preface to First Edition	<i>xviii</i>
About the Companion Website	<i>xx</i>

Part I Applied Preformulation 1

1 Mathematical Concepts 3

1.1	Introduction	3
1.2	Significant Figures and Rounding off Numbers	3
1.3	The Simple Linear Relationship	4
1.4	Exponential Rules	6
1.5	Logarithmic Rules	6
1.6	Differential Equations	7
1.7	Expanding and Reducing Formulas	9
1.8	Weights and Measures	9
	References	10
	Glossary	10

2 Thermodynamics 11

2.1	Introduction	11
2.2	The Zeroth Law of Thermodynamics	11
2.3	The First Law of Thermodynamics	11
2.4	The Second Law of Thermodynamics	12
2.5	The Third Law of Thermodynamics	13
2.6	Polymorphism	13
2.7	Physical Stability of Crystal Forms	14
2.8	Solubility	14
	References	15
	Glossary	16

3 Solubility and Dissolution 18

3.1	Introduction	18
3.2	Methods of API Solubility Enhancement	19
3.3	Nonionic, Ionic, and Acid–Base Concepts Related to Solubility and Dissolution	29
3.4	The Solubility of Gas in Liquid	29
3.5	The Solubility of Liquid in Liquid	30
3.6	The Solubility of Solid in Liquid	30
3.7	Disintegration and Dissolution	31
3.8	Concentration Units	34
3.9	The Partition Coefficient	39

3.10	Concluding Remarks	41
	References	41
	Glossary	44
	Appendix	45
4	Biological Aspects of Formulations	46
4.1	Introduction	46
4.2	Bioavailability and Bioequivalence	46
4.3	Protocols for Determining Bioequivalence	48
4.4	Bioequivalence Procedure	49
4.5	FDA-Approved Methods for Bioequivalence Studies	49
4.6	Approaches to Improving Bioavailability	50
	References	52
	Glossary	53
5	Interfacial Properties	54
5.1	Introduction	54
5.2	Liquid-Solid Interface	54
5.3	Liquid-Liquid Interface	55
5.4	Dosage-Form Applications	55
5.5	Case Study: HLB Determination	58
5.6	Case Study: Determination of Required HLB (rHLB)	58
	References	58
	Glossary	59
6	Adsorption Phenomenon	60
6.1	Introduction	60
6.2	Adsorption on Filters	66
6.3	Adsorption of Proteins	66
	References	66
	Glossary	68
7	Rheological Principles	69
7.1	Introduction	69
7.2	Newtonian Systems	69
7.3	Non-Newtonian Systems	70
7.4	Viscoelasticity	72
7.5	Reynolds Number	74
7.6	Concluding Remarks	76
	References	76
	Glossary	77
8	Chemical Stability and Shelf-Life Determination	78
8.1	Introduction	78
8.2	Shelf-Life Determination	79
8.3	Stability of Biotechnology Products	84
8.4	Compounded Products and Their Beyond-Use Dates	86
	References	102
	Glossary	107
9	Particle Science	108
9.1	Introduction	108
9.2	Micromeritics	108
9.3	Micronization	113

9.4	Particle Size Preparation and Reduction for Pulmonary Delivery	114
9.5	Polymeric Particulate Matter	115
9.6	Nanoparticles	116
9.7	Segregation of Particles	121
9.8	Case Studies: Microscopic Particle Size Analysis, Determining Statistically Valid Sample Size, and Comparison of Sieve and Focused Beam Reflectance Measurement Chord Length Particle Size Distributions	122
	References	126
	Glossary	129
10	Basic Statistics and Design of Experimental Concepts	130
10.1	Descriptive Statistics	130
10.2	Inferential Statistics	131
10.3	Statistical Applications in Quality Control Testing	135
10.4	Design of Experiment	136
10.5	Multivariate Analysis (MVA)	140
10.6	Reliability and Validity Assessment	152
	References	155
	Glossary	155
11	Formulation Development Concepts	157
11.1	Preformulation	157
11.2	Scale-up Considerations	164
11.3	Combination Products	168
11.4	Rate-Controlled Drug Delivery	170
11.5	Drug Delivery Technologies for Improving Oral Delivery	172
11.6	Drug Delivery Technologies for Improving Transmucosal Delivery	173
11.7	Drug Delivery Technologies for Transdermal Delivery	173
11.8	Special Considerations for Biotechnology and Protein Delivery Systems	174
11.9	Drug–Excipient and Excipient–Excipient Interactions	177
11.10	The Presence of Contaminants in a Formulation	178
11.11	Other Considerations	179
	References	179
	Glossary	184
	Part II Product Design	187
12	The Product Design Process	189
12.1	Introduction	189
12.2	Formulation Design	191
12.3	Process Design	194
12.4	Container Closure System Design	195
	References	196
	Glossary	198
12.A	Appendix	199
13	Tablet Product Design	214
13.1	Introduction	214
13.2	Formulation Design	220
13.3	Process Design	225
13.4	Container Closure System Design	249
13.5	Risk Management	255
13.6	Attribute Tests	256
13.7	New Drug Application Stability Assessment	257

	References	259
	Glossary	264
13.A	Appendix	265
14	Capsule Product Design	274
14.1	Introduction	274
14.2	Hard-Shell Capsules	274
14.3	Soft-Shell Capsules	288
14.4	Formulation and Process Optimization	291
14.5	Container Closure System Design	292
14.6	Risk Management	292
14.7	Attribute Tests	292
14.8	New Drug Application Stability Assessment	293
	References	293
	Glossary	295
14.A	Appendix	296
15	Dispersed System Product Design	298
15.1	Introduction	298
15.2	Formulation Design	298
15.3	Process Design	322
15.4	Container Closure System Design	325
15.5	Risk Management	325
15.6	Attribute Tests	326
15.7	New Drug Application Stability Assessment	327
	References	328
	Glossary	330
	Appendices	331
16	Aerosol Product Design	336
16.1	Introduction	336
16.2	Inhalation Formulation Design	338
16.3	Nasal, Buccal, Lingual, and Sublingual Aerosol Formulation Design	351
16.4	Container Closure System Design	354
16.5	Risk Management	356
16.6	Attribute Tests	356
16.7	New Drug Application Stability Assessment	359
	References	363
	Glossary	366
16.A	Appendix	367
17	Sterile Injectable Product Design	369
17.1	Introduction	369
17.2	Formulation Design	370
17.3	Process Design	393
17.4	Container Closure System Design	404
17.5	Risk Management	407
17.6	Attribute Tests	407
17.7	New Drug Application Stability Assessment	408
	References	409
	Glossary	415
17.A	Appendix	416

18	Ophthalmic Product Design	426
18.1	Introduction – Eye Anatomy and Physiology	426
18.2	Formulation Design	429
18.3	Process Design	436
18.4	Container Closure System Design	436
18.5	Attribute Tests	436
18.6	New Drug Application Stability Assessment	436
	References	436
	Glossary	438
18.A	Appendix	438
19	Transdermal Product Design	442
19.1	Introduction – Skin Anatomy and Physiology	442
19.2	Formulation Design	444
19.3	Conclusions	457
	References	457
	Glossary	459
19.A	Appendix	459
20	Oral Modified-Release Product Design	462
20.1	Introduction	462
20.2	FDA and U.S.P. Nomenclature	462
20.3	Modified-Release Mechanisms	464
20.4	<i>In Vitro–In Vivo</i> Correlations (IVIVC)	465
20.5	Coatings	466
20.6	Matrix Systems	467
20.7	Gastroretentive Devices	470
20.8	Osmotic-Controlled Release Systems	470
20.9	Conclusions	471
	References	471
	Glossary	472
20.A	Appendix	473
Part III Regulatory Science		475
21	Regulatory Practices and Guidelines	477
21.1	Worldwide Regulatory Agencies	477
21.2	Good Manufacturing Practice (GMP)	484
21.3	FDA Inspection and Regulatory Actions (FDA 2020b, 2020d)	503
	References	510
	Glossary	511
21.A	Appendix	519
22	Regulations for Compounding Pharmacies	525
22.1	Introduction	525
22.2	Sections 503A and 503B and Their Differences (FDA 2018a)	526
22.3	Compounding Guidelines	526
22.4	Good Compounding Practices (FDA 2007; Skoloff 2009; U.S.P. <795> 2020; U.S.P. <797> 2020); U.S.P. <1191> 2018; USP29 2006; USP29NF24 2006; OSBP 2017; NDBOPH 2020; NV 2020a; OR 2020; CPE 2017; OK 2020; KY 2016a; WA 2020a; FDA 2020a, 2020b)	527
22.5	Compounding Sterile Preparations (U.S.P. <797> 2020; WA 2020b; CT 2020; OR 2020; NV 2020b; OK 2020; KY 2016b; NYBOP (n.d.); ASPH 2003, 2020; TU n.d.)	532

- 22.6 Stability Criteria and Beyond-Use Dating of Compounded Non-Sterile Preparations (U.S.P. <797> 2020; WA 2020b; CT 2020; OR 2020; NV 2020b; OK 2020; KY 2016b; NYBOP (n.d.); ASPH 2003, 2020; TU n.d.) 536
- 22.7 Verification (U.S.P. <795> 2020; U.S.P. <797> 2020; WA 2020a, 2020b) 537
- 22.8 Patient Counseling (U.S.P. <795> 2020; U.S.P. <797> 2020; WA 2020a, 2020b) 537
- 22.9 Patient Monitoring and Adverse Events Reporting (U.S.P. <797> 2020; WA 2020b) 537
- 22.10 Pharmacy Compounding Accreditation 537
- 22.11 Compounding: Inspections, Recalls, and Other Actions (FDA 2018b; FDA 2018c) 538
 - References 538
 - Glossary 540
- 22.A Appendix 541

- 23 IND and NDA Phase-Appropriate New Drug Development Process 554**
- 23.1 Introduction 554
- 23.2 Preclinical Development Overview (FDA 1998) 555
- 23.3 Phase-Appropriate Clinical Trials Overview (FDA 1998) 556
- 23.4 Investigational New Drugs 558
- 23.5 Good Laboratory Practice for Nonclinical Laboratories Studies [21CFR58] (FDA 2020c) 564
- 23.6 CGMP for Phase 1 Investigational Drugs – Guidance for Industry (FDA 2008) 566
- 23.7 Good Clinical Practice [E6(R2)] Guidance for Industry (FDA 2016, 2018, 2019a) 568
- 23.8 NDA Review Process (FDA 1998) 570
 - References 574
 - Glossary 575
- 23.A Appendix 576

- 24 Biological, Biosimilar, Generic, and OTC Products 584**
- 24.1 Biologicals (FDA 2015a, 2015b, 2016b 2018a, 2018b, 2019a, 2019b, 2019c, 2020a; EMA 2019) 584
- 24.2 Biosimilars (EMA n.d.-a, n.d.-b; FDA n.d.-a, n.d.-b; Christl n.d.; FDA n.d.-c; Lim n.d., 2013; FDA 2017a, 2017b, 2017c, 2018c, 2020b, 2020c; EMA 2019) 586
- 24.3 Generic Drugs (FDA 1998a, 2014b, 2017f, 2017g, 2018e, 2018g, 2019d) 588
- 24.4 Over-the-Counter Drugs (FDA 1998b, 2016a, 2018g, 2019f, 2020e, 2020f, 2020g) 593
 - References 598
 - Glossary 600
- 24.A Appendix 602

- 25 Accelerated New Drug Approval and Expedited Access of New Therapies 605**
- 25.1 Introduction 605
- 25.2 Expedited Review and Approval of New Therapies (HIV n.d.; IOM 1991; FDA 2009a, 2010a, 2011b, 2014) 605
- 25.3 Expanded Access to New Therapies (HIV n.d.; FDA 2009a) 607
- 25.4 Orphan Drugs (EMA n.d.-a, n.d.-b; WebMD n.d.; FDA 1998a, 2005a, 2018, 2018b, 2020c; IOM 2010) 608
- 25.5 Pediatric Drugs (FDA 1998b, 2005b) 610
- 25.6 Pediatric Drug Development and the Orphan Drug Act Incentives (FDA 2010c) 612
- 25.7 Common EMEA/FDA Application for Orphan Medicinal Product Designation (EMA n.d.-a, n.d.-b; FDA 2009b; FDA 2018) 612
 - References 613
 - Glossary 614

- 26 Post-Drug Approval Activities 617**
- 26.1 Postmarket Requirements and Commitments (FDA 2016b, 2018f, 2020a, 2020e) 617
- 26.2 Postapproval Manufacturing Changes (FDA 2018d, 2020b) 618
- 26.3 Clinical Phase 4 Studies: Postmarketing Surveillance and Risk Assessment (FDA 2018d, 2019b) 619
- 26.4 Prescription Drug Advertising and Promotional Labeling Direct to Consumers (FDA 1998c) 622
 - References 623
 - Glossary 624
- 26.A Appendix 626

27	Drug Master Files, EU Dossiers, and API GMP Guidance	627
27.1	Drug Master Files (FDA 2001, 2011a, 2011b, 2011c, 2011d, 2011e)	627
27.2	European Marketing Authorization Dossiers	633
27.3	Good Manufacturing Practice (GMP) Guidance for Active Pharmaceutical Ingredients (Q7) (FDA 2016)	636
	References	641
	Glossary	643
28	Commissioning and Qualification	646
28.1	Regulatory Requirements (Health Canada 2009; EU 2015; FDA 2017, 2018a, 2020)	646
28.2	Preliminary C&Q Activities	647
28.3	Commissioning	649
28.4	Qualification and Validation	651
28.5	Qualification Protocols (ISPE 2001; Health Canada 2009; PIC/S 2018)	653
28.6	Process Validation (FDA 2014, 2019; PIC/S 2018)	657
28.7	Cleaning Validation (Health Canada 2008; FDA 2014, 2017; PIC/S 2018)	659
28.8	Computer Systems Validation (ISPE 2001; EU 2011)	660
28.9	Change Control (EU 2015; PIC/S 2018)	660
28.10	Revalidation (CDRH 1995; EU 2015; FDA 2015; PIC/S 2018)	661
	References	661
	Glossary	663
29	Quality Systems and Controls	666
29.1	Pharmaceutical Quality System (FDA 2019a)	666
29.2	Quality Systems Approach to CGMP Regulations	669
29.3	Inspection of Pharmaceutical Quality Control Laboratories (FDA 2014)	672
29.4	Pharmacopeias (U.S.P. 2014)	673
29.5	Analytical Instrument Qualification (U.S.P. <1058> 2019a; FDA 2010)	676
29.6	Validation of Analytical Procedures (U.S.P. <1225> 2019b; FDA 2000, 2015, 2019b)	679
29.7	Stability Testing of New Drug Substances and Products (U.S.P. <1150> 2006; ICH 1996; FDA 2018b, 2018c, 2018d)	680
29.8	Electronic Records; Electronic Signatures (Part 11) (FDA 2019)	682
	References	684
	Glossary	686
29.A	Appendix	690
30	Safety, Toxicology, and Pharmacogenomics	696
30.1	Nonclinical Safety Studies (ICH 2009; FDA 2010)	696
30.2	Safety Pharmacology Studies (ICH 2000)	697
30.3	Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals – (FDA 1997; EMA 2011a)	700
30.4	Carcinogenicity Studies of Pharmaceuticals (ICH 1995)	701
30.5	Genotoxicity Testing (ICH 1998, 2008)	702
30.6	Immunotoxicity Studies (ICH 2005b)	704
30.7	Safety Reporting Requirements	705
30.8	Pharmacogenomics (NIGMS 2005; ICH 2005b; ORNL 2010)	706
30.9	Pharmacovigilance (EMA 2011b, 2015, 2021; Eudro n.d.; FDA 2005c, 2005d)	709
30.10	FDA’s Predictive Toxicology Roadmap (FDA 2017, 2020)	711
	References	711
	Glossary	713
	Appendix	716
31	Regulatory Science Initiatives for Advancing Public Health	719
31.1	Introduction	719
31.2	Advancing Regulatory Science for Public Health – A Framework for FDA’s Regulatory Science Initiatives (FDA 2010)	719

- 31.3 Advancing Regulatory Science at FDA – A Strategic Plan (FDA 2018b, 2018c, 2018d, 2018e, 2018f, 2018g, 2018h, 2018i, 2018j, 2018k, 2018l) 719
- 31.4 A Collaborative Implementation Framework (FDA 2010, 2011, 2018n) 723
References 724

- 32 Medical Devices 726**
- 32.1 Introduction (FDA 2018a, 2019a, 2020a) 726
- 32.2 Device Determination Steps (FDA 2019a, 2020a) 726
- 32.3 Classification and Regulatory Requirements (FDA 2018b, 2020b) 727
- 32.4 Current Good Manufacturing Practices (CGMPs) and Quality System Regulation (QSR Regulation) Requirements 729
- 32.5 Medical Device Complaint Reporting and Recalls (FDA 2019h, 2019i) 731
References 731
Glossary 732

- 33 Combination Products 735**
- 33.1 Introduction (FDA 2018, 2019e, 2020) 735
- 33.2 Product Jurisdiction/Assignment of Combination and Non-Combination Products (FDA 2019a, 2020) 736
- 33.3 Premarket and Marketing Applications (21 CFR Parts 312 and 812) (FDA 2019b, 2019c, 2020) 736
- 33.4 Current Good Manufacturing Practice – Subpart A (21CFR4) (FDA 2019d) 737
- 33.5 Postmarketing Safety Reporting for Combination Products [21CFR4/Part 4 Regulation of Combination Products/ Subpart B] (FDA 2019d) 737
References 738
- 33.A Appendix 739

- 34 Dietary Supplements 740**
- 34.1 Introduction (FDA 2017a, 2019a, 2019b) 740
- 34.2 Dietary Ingredients (FDA 2019a, 2019b, 2019c) 740
- 34.3 Dietary Supplement Ingredient Advisory List (FDA 2019d) 741
- 34.4 DS Labeling: Claims Types and Requirements (FDA 2017b, 2018, 2019e) 741
- 34.5 Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements (21 CFR Part 111) (FDA 2019f) 741
- 34.6 FDA Inspection and Regulatory Actions (see – 21.3 FDA Inspection and Regulatory Actions – see Chapter 21 for details) 745
References 745
Glossary 745
- 34.A Appendix 746

- 35 Animal Drugs and Devices 751**
- 35.1 FDA Center For Veterinary Medicine (CVM) (FDA 2019a) 751
- 35.2 Animal Drug Availability Act of 1996 (FDA 2019b) 751
- 35.3 Development and Approval Process (FDA 2017, 2020a) 752
- 35.4 CGMP and Others Compliance Requirements 756
- 35.5 Animal Drug Manufacturing Inspection – Pre-Approval (FDA 2006) 756
- 35.6 PostMarketing Surveillance (FDA 2017, 2019d, 2020a) 756
References 757

Foreword to Second Edition

The breadth and depth of pharmaceuticals is expertly covered by this well-written and organized second edition of *Integrated Pharmaceutics: Applied Preformulation, Product Design, and Regulatory Science*. This book should be required reading for educating our next generation of pharmaceutical scientists as it provides up-to-date discussion, explanation, relevant examples, and case studies of a plethora of important topics required for both academic and industrial scientists. Part I, which covers preformulation aspects that must be considered when developing a drug into a product, includes expanded content of such critical concepts as solubility and dissolution, bioavailability and bioequivalence, interfacial properties, adsorption phenomenon, rheological principles, chemical stability and shelf-life determination, particle science, statistics as related to experimental design, and formulation development concepts. Following in a logical sequence, Part II then provides in-depth instruction directly related to the design and development of specific dosage forms, including tablets, capsules, dispersed systems (e.g. suspensions, emulsions, colloids), aerosol products (including a helpful section on excipients used in aerosol products), sterile injectable products, ophthalmic products, transdermal products, and oral modified-release products (including specific examples of coated and matrix modified-release systems). These chapters will be particularly useful to undergraduate and graduate students in pharmaceuticals, pharmacy, and engineering. Lastly, Part III wraps up the book with a comprehensive discussion of the regulatory sciences that every

pharmaceutical scientist should have a working knowledge of, including discussion of regulatory practices and guidelines for regulatory agencies around the world, application of regulations for compounding pharmacies, processes involved in IND and NDA drug development studies, regulatory requirements for biological, biosimilar, generic and OTC products, accelerated NDA and expedited access for new therapies, guidance related to drug master files, EU dossiers and API GMP processes, commissioning and qualification, overall quality systems, safety, toxicology and pharmacogenomics studies related to product approval, and discussion of medical devices, combination products, dietary supplements and animal drugs, and devices. It is evident that this second edition provides the reader with important and current aspects of the science involved in successfully developing a pharmaceutical product. As a 35-year veteran industrial and academic pharmaceutical scientist, I commend the authors for having provided this expertly written and updated contribution to the pharmaceutical sciences.

*Robert O. (Bill) Williams III, PhD
Johnson & Johnson Centennial Chair and Professor
Division Head, Molecular Pharmaceutics and
Drug Delivery
The University of Texas at Austin,
College of Pharmacy Editor-in-Chief,
AAPS PharmSciTech FAAPS, FAIMBE, FNAI*

Foreword to First Edition

The wide variety of topics covered by the authors in this book emphasize both the depth and breadth of knowledge needed for pharmaceutical scientists to bring a drug product to the marketplace successfully. The challenge of designing and developing compounds into pharmaceutical products, which are critical to the survival of both the biotech and pharmaceutical industries, will depend largely on the education and extensive training required for young pharmaceutical scientists. This book gives the reader an understanding of the basic and applied sciences involved in the development and approval of a pharmaceutical product through regulatory authorities. Unfortunately, these topics have slowly lost their emphasis over the past several years in graduate courses taught in our colleges of pharmacy.

The eleven chapters in Part I cover preformulation topics, wherein the physical and chemical properties of a drug substance, along with its stability and interactions with excipients and the biological aspects of the formulations, are discussed in detail. These and other preformulation topics covered in this section outline the basic properties that fingerprint both the characteristics of a drug substance and the

properties of ingredients that must be considered when formulating a physically and chemically stable dosage form. Part II, Chapters 12 through 20, covers product design topics. The regulatory science aspects of drug development are covered in Chapters 21 through 31. This is yet another area that has received minimal attention in graduate schools.

For both the academic and industrial scientists, and graduate students whose research is focused in this field, the authors have emphasized important aspects of materials science and processing that must be addressed for a successful product introduction following approval through regulatory authorities. The chapters in this book flow extremely well and provide very useful information not only to undergraduate and graduate students in pharmaceuticals, pharmacy, materials sciences, and engineering but also to faculty and industrial scientists in these disciplines.

*James W. McGinity, PhD
Professor of Pharmaceutics
The University of Texas at Austin*

Preface to Second Edition

The second edition of *Integrated Pharmaceutics: Applied Pre-formulation, Product Design, and Regulatory Science* expands on the original edition and emphasizes greater integration among the three main sections of the textbook. It is still our intention for the text to deliver valuable material to practitioners, pharmaceutical scientists, and graduate students engaging in research and learning in pharmaceutical sciences in general and pharmaceutics/industrial pharmacy as a major. To that end, this new edition of the book continues to serve those engaged in designing pharmaceutical drug products. The new material added to the second edition reflects suggestions we heard from colleagues and students and the latest trends in the development of dosage forms. While no text can claim complete inclusion of all material on a given subject, the reader of this second edition can find it more comprehensive in its delivered information. The unique integration of regulatory affairs considerations related to product design discussions continues to be featured. While we added newer material to the text, some of the less helpful content was excluded from this edition. Readers may refer to the first edition if they desire to access these omitted topics.

The reader will find that the new edition still contains the basic information that is necessary to formulate a pharmaceutical dosage form. The second edition expands on these topics by making each chapter more comprehensive. Specifically, some of the modifications made on the first edition that are found in this current edition incorporate the following: methods of API solubility enhancement, nonionic, ionic, and acid–base concepts related to solubility and dissolution; interactions involved the drug’s states of matter (solid, liquid, and gas) in a formulation structure and the influence of these interactions on the biological aspects of formulations; liquid–liquid interface, formulation and optimization techniques, and determination of HLB values; data handling in rheometry and the use of rheometry in reverse engineering of a topical dosage form are explored; expanded information on the theoretical aspects of drug stability that include chemical equilibrium theories and applications; particle dimension, types of particle diameter, and the use of particle diameters in formulation development; more examples on statistical analysis, in particular applications related to using JMP® Statistical Discovery Software, Version <14.0>, SAS Institute Inc., Cary, North Carolina in analyzing and interpreting data related to drug development; process analytical technologies (PATs) and scale-up methodologies; vaccines technology; formulation and process designs, container closure characteristics,

various attribute tests, and stability assessment of the final ophthalmic product; FDA inspection and CGMP check list; comparison of regional (EMA, China, FDA, Japan, and WHO) GMP chapters; the recent regulations governing compounding (503A and 505B), USP Chapter 797, compounding sterile preparations, self-inspection/audit, and a check list (questionnaire); Part 58 (Good laboratory Practice), CGMP for Phase 1 investigational drugs (Guidance for Industry), sterile drug products produced by aseptic processes (CGMP Guidance for Industry), and ICH E6 (R2) Good Clinical Practice; 21 CFR 320 Bioavailability and Bioequivalence requirements as well as development and approval of biosimilars in the USA and EU; Emergency Use Authorization; Orphan Drugs regulations; risk-based qualifications; Part 820 Quality Systems regulations, Part 820 QSR-Auditor’s Check List, and Part 11 Electronic Records/Electronic Signature and Auditor’s Check List; GMP guidance (Q7) for APIs. In addition, ICH Q9-Quality Risk Requirement; pharmacovigilance for medical products and the predictive toxicology roadmap; innovation measures for public health adopted by the FDA and critical path initiatives; Part 601 pertaining to licensing biologicals and Part 610 dealing with general biological products standards; Regulations, CGMPs, and guidance covering medical devices, combination products, dietary supplements, and veterinary drugs and devices as enforced by the regulatory authorities in the USA.

Acknowledgments

All the illustrations and the artwork in this text were produced by Mr. Scott Staton, Production Manager (Pharmaceutical and Educational Research Center; Campbell University). The authors are grateful to his fine contributions and of Ananya Agrawal, BITS Pilani, India, for Appendix 23.A.1. Special thanks go to Mr. Jonathan Rose (Senior Editor, Academic Publishing Group), Ms. Mandy Collison (Managing Editor), and Mr. Sundaramoorthy Balasubramani (Content Refinement Specialist) from Wiley for their excellent professional assistance in publishing this edition. We are appreciative of all the input we have received from colleagues and students concerning the subject matter presented herein.

alachi@campbell.edu
guptam@campbell.edu
stagnerw@campbell.edu

Antoine Al-Achi
Mali Ram Gupta
William Craig Stagner

Preface to First Edition

The idea for this book was born out of the authors' desire to create a textbook to be used for several courses in our pharmaceutical science BS/MS curriculum and cooperative BS/MS engineering/pharmaceutical sciences program approved by North Carolina State University, Raleigh, North Carolina, and Campbell University, Buies Creek, North Carolina. The book will also be used as part of the College of Pharmacy & Health Sciences Pharm.D. program. The book's theme and scope focus on the application of the principles of physical pharmacy, product design, and regulatory science and how they relate in an intricate web to produce effective dosage forms that deliver drugs to their site of action. Currently, there is a critical shortage of pharmaceutical scientist specialists in product design and related technologies. Historically, most pharmaceutical scientists were educated in pharmacy schools. These programs integrated biology, pharmacology, chemistry, mathematics, physics, and materials science with one overarching goal: drug delivery to treat the human condition. A majority of the Ph.D. pharmaceutical scientists were educated as B.S. pharmacists. Over the past 30 years, pharmacy education has become more drug therapy focused and less drug delivery oriented. Federal funding has also followed this trend, leaving unprecedented shortages of academic pharmaceutical scientists. In addition, the shift in pharmacy education emphasis has required that the pharmaceutical industry hire chemists, biologists, and engineers who do not have the benefit of the integrated educational program that was once offered by schools of pharmacy. These employees are trained (not educated) on the job, although some schools of engineering are trying to fill some of the educational void.

The novel approach of this book is, as much as possible, to integrate international harmonized pharmaceutical development regulatory guidelines and requirements with the science and technology of pharmaceutical product design. New regulatory guidelines such as quality by design, design space analysis, process analytical technology, polymorphism characterization, blend sample uniformity, stability protocols, and the biopharmaceutical classification system are integrated throughout the text.

In Part I, we present the fundamentals of physical pharmacy and preformulation as they apply to pharmaceutical dosage form design. Topics such as thermodynamics, drug solubility, drug stability, rheological aspects of formulation, interfacial science, bioavailability, and others are covered in this part. Other chapters cover basic mathematical, statistical, and design-of-experiment concepts.

In Part II, we elaborate on the complex multifactorial process that brings together drug delivery to treat a human condition with formulation, manufacturing process, and container closure system design. The inextricable interrelationships among the formulation, the process, and the container closure system are emphasized by integrating each of these product design features into a single dosage-form chapter. Unification of appropriate preformulation and regulatory science applications is also highlighted. A similar format is incorporated for most chapters: an introduction that discusses the relevant anatomical and bodily function that affect drug delivery, advantages and disadvantages of the product, formulation design that examines dosage-form-specific preformulation, excipient compatibility, formulation development; process design, relevant process analytical technologies, pertinent scale-up models and practices, container closure system design incorporating critical patient and product considerations, risk management, in-process and final product attribute tests, and new drug application stability assessment programs. Most chapters include extensive reference appendixes of functional excipients, their compendial status, and usage levels. Other reference appendixes include surfactant hydrophile-lipophile balance (HLB) values, oil-required HLB values, sequestering agent stability constants, lyophilization bulk-ing agents, and eutectic and collapse temperatures.

Part III covers regulations as specified by the U.S. Food and Drug Administration (FDA), European Medicines Agency, and other international regulatory agencies. This part provides a broad spectrum of topics from compliance requirements (current good manufacturing and good laboratory practices, and others), International Conference on Harmonization and other global harmonization initiatives, the investigational new drug (IND) and new drug

application (NDA) phase-appropriate new drug development process, pre- and post-approval processes (INDs, NDAs, abbreviated NDAs, and drug master files), accelerated approval and initiatives for orphan and pediatric drug development, post-drug approval activities, quality system controls, commissioning and qualification (of facilities, equipment, analytical instruments, and test methods, among others), regulatory requirements for all facets of extemporaneous compounding (from handling of prescription for compounding to patient counseling), recommendations for conducting and reporting results of nonclinical and clinical safety and toxicology studies, barriers and benefits of pharmacogenomics studies, to the most recent FDA initiative on regulatory science.

In summary, the book introduces a fresh approach to presenting industrial pharmacy by combining physical pharmacy, product design, and regulatory science issues in a single compendium. The authors hope that the integrated perspective presented will be useful for undergraduate, graduate, and professional pharmacy students and will provide pharmaceutical scientists with a reference resource. The authors will also greatly appreciate feedback and comments that lead to improvements in the book.

Acknowledgments

The authors wish to thank Bob Stagner for reviewing Chapters 12 through 20, 23, 25, and 26 and for providing constructive suggestions, and Paul Johnson for reviewing and providing helpful suggestions on chapters 23 and 29. The authors are also indebted to Drs. Keith Johnson and Larry Gatlin for their expert advice on Chapters 16 and 17, respectively. Special thanks go to Scott Staton for his tireless effort in preparing the excellent illustrations.

The authors appreciate the unwavering support of their department chair, Dr. Emanuel Diliberto. We also acknowledge the help of our graduate students in this endeavor.

alachi@campbell.edu
guptam@campbell.edu
stagnerw@campbell.edu

Antoine Al-Achi
Mali Ram Gupta
William Craig Stagner

About the Companion Website

This book is accompanied by a companion website

www.wiley.com/go/Al-Achi/IntegratedPharmaceutics



The website includes:

- Study guide
- List of equations.

Part I

Applied Preformulation

1

Mathematical Concepts

1.1 Introduction

Pharmacy as a profession is art, business, and science. The science of pharmacy, also known as *pharmaceutical science*, requires knowledge of mathematics. Experimentation in pharmaceutical science produces quantitative measures with specific values. Handling these measures mathematically depends on how to apply rules to define them. In turn, these definitions of measures lead to a description of experimental entities. For example, to define a solution's pH, a pH meter is normally used in the measurement. Knowledge of the pH value can define the concentration of hydronium ions present in the solution. The relationship that allows transformation of the pH value to a concentration term is a mathematical expression known as *Sørensen's equation*:

$$\text{pH} = -\log [\text{H}_3\text{O}^+] \quad (1.1)$$

If the pH meter reads pH 10.8 for the solution, Eq. (1.1) may be used for the determination of $[\text{H}_3\text{O}^+]$:

$$\begin{aligned} 10.800 &= -\log [\text{H}_3\text{O}^+] \\ [\text{H}_3\text{O}^+] &= 1.58 \times 10^{-11} \text{M} \end{aligned}$$

Thus, the concentration of hydronium ions in solution was computed from Eq. (1.1) by mathematical manipulation employing the rules of logarithms. The mathematical operator “p” represents the function $(-\log)$ in the equation. Thus, $(-\log [\text{H}^+])$ becomes pH.

Mathematical rules can also aid a pharmaceutical scientist in describing the blood profile following administration of a drug in patients. Following intravenous administration of a drug, the drug is placed in circulation and achieves its highest concentration immediately following injection. The concentration of the drug decreases thereafter through distribution to tissues and via metabolic pathways. The drug disappearance from the circulation over time may be described by an exponential function following the general expression

$$C_{\text{blood}} = C_{\text{initial}} e^{-kt} \quad (1.2)$$

where C_{blood} is the drug concentration at time t , C_{initial} is the initial concentration of the drug in the blood immediately following administration, and k is the elimination rate constant. Equation (1.2) can be made linear by converting it to its logarithmic form:

$$\ln C_{\text{blood}} = \ln C_{\text{initial}} - kt \quad (1.3)$$

The transformation of Eq. (1.2) to Eq. (1.3) requires knowledge of the rules of logarithms. *Pharmacokinetics*, which is the study of drug absorption, distribution, and elimination, uses these mathematical manipulations of data to improve patients' therapeutic outcomes. Equation (1.3) describes a linear relationship between the natural logarithm of drug blood concentration and time. This linear relationship is not only important in pharmacokinetics, but its applications are well utilized in physical pharmacy applications.

In this chapter, we cover the major important mathematical concepts that pharmaceutical scientists utilize in their studies. With the advancement of computer technology, many of these mathematical applications are handled by a computer software program or even by a basic scientific calculator.

1.2 Significant Figures and Rounding off Numbers

The United States Pharmacopeia (USP) emphasizes on the use of significant figures in reporting numerical results. To that end, the reader is encouraged to consult the USP or other resources concerning this topic for more details. The following rules apply to reporting values obtained from mathematical manipulations of data:

- 1) Intermediate numerical values may be retained to their original decimal figures and the final results are then reported to the significant figures desired.

- 2) Zero value may or may not be significant depending on the way it is being reported. A significant zero is emphasized in the number being reported, such as in 109.0 mg. The zero in this number is significant, and thus there are four significant figures in 109.0 mg. However, the zero value appearing immediately after the decimal point in 0.0109 mg is not significant, thus this number has only three significant figures. And the number 0.0009 mg has only one significant figure.
- 3) In the value such as 1090 mg, the last zero may or may not be considered an approximate digit, depending on the method of analysis being used.
- 4) When performing mathematical operations, the final number is reported with the least number of significant figures used to generate that number. For example, multiplying 3.40 (three significant figures) by 208.0 (four significant figures) results in the value of 707.2, which should be reported as 707 (the 2 in the final number is not significant). However, if one of the numbers is an absolute value, such as the case with the number of tablets in a bottle, then the final result is reported to the next possible significant figures in the operation. For example, 34 tablets (exact number) of a multivitamin product were reported to have in each tablet 50.00 mg (four significant figures) of vitamin C. Then, $34 \times 50.00 = 1700$ mg (four significant figures).
- 5) Rounding off the final number to the desired significant figures: If the final number is reported to three significant figures, and the final number was 89.87, then this value would be rounded off to 89.9; likewise if the number is 89.83, it is rounded off to 89.8. Notice that we added (+1) in first case when the last digit was greater than 5 (the same rule applies if the last digit was exactly 5), and we dropped the digit from the answer when the number was less than 5.
- 6) For logarithms, the number of significant figures in the antilogarithm equals the number of digits in the mantissa. For example, if $\log x = 10.800$ (three significant figures in the mantissa/the part of the number that follows the decimal point), the antilogarithm value would be reported as 6.31×10^{10} (notice that the value 6.31 has three significant figures).

1.3 The Simple Linear Relationship

When two variables x and y vary with each other linearly, their function may be written as

$$y = a + bx \quad (1.4)$$

where y is the dependent variable and x is the independent variable. The slope of the line is b , and the y -intercept is a . The coefficient b can be positive or negative in value. When

b is positive, an increase in x results in an increase in y . Conversely, if b is negative, an increase in x produces a decrease in y . Although Eq. (1.4) can be found manually, the usual method is to input the y and x values into a computer program to generate a linear equation. For example, the following data were obtained from a spectrophotometric experiment measuring the concentration of aspirin in solution:

Concentration (mg/mL)	Absorbance
0.0325	0.003
0.0650	0.006
0.1250	0.011
0.2500	0.023
0.5000	0.049

To obtain the linear relationship between concentration and absorbance, a simple scientific calculator may be used. The following equation is obtained:

$$\text{Absorbance} = -0.0008 + [0.1 \times \text{concentration (mg/mL)}] \quad (1.5)$$

Comparing Eq. (1.4) with Eq. (1.5), the absorbance value is the dependent variable and the concentration is the independent variable. The y -intercept is negative in this case, and statistically speaking, is not different from zero. The coefficient b is positive, which is expected from relationships that represent Beer's law (Figure 1.1). It is important always to check whether or not the mathematical relationship adheres to the scientific norms. Using Eq. (1.5), the concentration of aspirin in an unknown solution may be estimated. For example, if the absorbance of an unknown solution of aspirin is 0.015, the estimated concentration of aspirin in solution is




Figure 1.1 Positive linear relationship between the concentration of aspirin in solution and absorbance readings. Data points are experimental values, and the solid line is the best-fit line for the data.

- self-containment 210(a), 228, 230
 Shapiro compression profile 244
 Shapiro's compression parameter 244
 solidification time 243
 tablet-formation sequence 215
 tableting
 compression–time profile 244
 contact time 244, 245
 dwell time 243, 246
 ejection time 244
 elastic yield pressure 244
 feed frame 217
 tablet problems 164, 214, **219**, 234, 244, 245, 621–622, 756–757
 tablet tool and die design 245
 temperature increase during tableting 245
 time–resolved compression 244
 Tamper-evident packaging
 Requirements for over-the-counter (OTC) human drug products
 [Sec. 211.132] 492, 522(a),
 597, 737
 Tamper-resistant packaging requirements (TRP) for certain over-the-
 counter human drug products 492, 507, 596–598
 Tamper-resistant packaging 507, 596–598
 Tangent loss (microwave drying) 72, 73, 242, 243
 Tapped bulk density 115, 124
 Tapped density 113, 193, 245, 281, 283, 292, 302, 339, **371**
 Taste 31, 140–145, 172, 207(a), 210(a), **222**, 246–248, 275, 299, 300, 304,
 305, 314, 319, 323, 324, 339, 352, 353, **357**, 692(a), 750(a)
 score 324
 T-cell dependent antibody response 705
 Tear fluid surface tension 430
 Tear pH 429
 Technical information and content by DMF type
 type I DMF 629
 type II DMF 629, 630
 type III DMF 629–630
 type IV DMF 627, 630
 type V DMF 630
 Technology transfer 194, 666, 667, 690(a), 691(a)
 Teicoplanin **99**
 Temozolomide **100**
 Temperature coefficient of microbial destruction
 400, 416(a)
 Terbutaline sulfate **100**
 Terminal velocity 300, 306
 Testim gel 447, 448
 Testing and approval or rejection of components, drug product
 containers, and closures [Sec. 211.84] 488–489, 522(a), 737
 Testing and release for distribution [Sec. 211.165] 493, 523(a), 737
 Testing, adjusting and balancing 655
 Testosterone **100**, 446–448
 Tetracaine **100**, 450
 and clotrimazole combination **100**
 Tetracycline hydrochloride 34
 Texture 72, 73, 111–113, 256, 319, 326, 456
 Theoretical yield 490, 496, 506, 508, 516, 517, 519(a)
 percentage of 516
 Therapeutic Equivalence Evaluations 589
 Therapeutic Inequivalence Action Coordinating Committee 622
 Therapeutic inequivalence reporting 622
 Thermal ablation 450, 456
 Thermal analysis 13, 15, 223
 Thermal penetration enhancement 450–451
 Thermal treatment 317, 391–392
 Thermodynamically stable 13, 14, 18, 169, 300, 301, 306, 317, 319
 Thermodynamics 9, 11–19, 26, 40, 56, 57, 65, 169, **219**, 247, 299–303,
 305, 306, 310, 314, 315, 317, 319, 325, 350, 391, 399
 Thermodynamic solubility 14, 17
 Three-dimensional printing 469
 Timoptic-XE 431
 Thioguanine **100**
 Third law of thermodynamics 13
 Thixotropy 71, 355
 Thymopentin 51
 TIACC, *see* Therapeutic Inequivalence Action Coordinating Committee
 Time limitations on production [Sec. 211.111] 522(a)
 Time to threshold 454
 Title 21 of the Code of Federal Regulations 47, 49, 192, 217, 233, 248,
 251, 252, 354, 405–407, 436, 477, 485, 573, 591, 605, 617, 627,
 669, 699, 729
 TOPAS, *see* Container closure system; Cyclic olefin polymer
 Total internal reflection fluorescence 60
 Total yeast and mold count 326
 Toxicology 191, 555, 556, 560–563, 571, **582**, 595, 627, 674, 696–711,
 717, 720, 721, 728
 Tranexamic acid **100**
 Transdermal product design
 advantages and disadvantages 442, **443**
 anatomy of skin 442–444
 epidermis (100 to 150 microns) 442, 455
 dermis (1000 microns) 455
 subcutaneous fatty tissue 442
 Androgel 446, 448
 anodal delivery 451
 azone 447, 459(a)
 cathodal delivery 451
 Collectra electroporation system 453
 chemical penetration enhancers 446–447, 453, 457
 clonidine patch 444, 448–449
 Companion 80 iontophoresis system 453
 controlled heat-assisted drug delivery system 450
 cumulative drug permeation 446
 Deponit 449
 diffusion coefficient 445, 450, 454
 Dupel iontophoretic system 453
 Duragesic 446, 449
 elastic niosomes 449
 electropermeabilization 453
 Elgen electroporation system 453
 E-trans iontophoretic system 452
 enhancement 447, 450–457
 estradiol 444, 448
 ethosomes 450
 Evamist 448

Transdermal product design (*cont'd*)

- Faraday's law 451, 452
- fentanyl patch 449
- Fick's first law 444
- flux (effect of)
 - apparent diffusion coefficient (effect of)
 - Boltzmann's constant 445
 - radius of drug particle 33, 445
 - temperature 6, 11, 29, 58, 69, 79–82, 84, 85, 120, 224, 227, 245, 279, 301, 311, 314, 319, **341**, 346, 349, **372**, 380, 390, 394–396, 398, 445, 450, 681
 - viscosity 430
 - area 32, 452
 - drug concentration in formulation 47, 48, 56, 280, 380, 429, 432, 444, 445, 452, 456
 - thickness of permeation membrane 442, 445
- frictional coefficient 445
- Habitrol 449
- hollow microstructure transdermal system (hMTS) 455
- Intraject needle-free injection system 456
- Iontopatch wearable electronic disposable drug delivery system 453
- iontophoresis penetration 451–453
- IONSYS iontophoretic system 453
- lag time (effect of)
 - apparent diffusion coefficient 431, 445
 - thickness of diffusional membrane 29, 32, 445
- laser ablation permeation enhancement 456
- LidoSite iontophoretic system 453
- liposomes 449, 450
- MacroFlux microneedles system 455
- microdermal abrasion permeation enhancement 456–457
- microneedle penetration enhancement 455–456
- needle-free injector 456
- Nicoderm CQ 449
- nicotine patch 449
- niosomes 449
- Nitro-Dur 449
- nitroglycerin patch 449
- Ohm's law 452
- Passport thermal ablation system 456
- partition coefficient 443–445, 448, 449
- patches
 - adhesive 173, 443, 448, 449
 - reservoir 434, 448, 449
 - layered 448, 449
- Pennsaid 447, 448
- permeation enhancement
 - ablation 454, 456
 - thermal 450–451
 - laser 455, 456
 - radiofrequency
 - abrasion 456–457
 - chemicals 457
 - electroporation 450, 453, 457
 - electropermeabilization 453
 - iontophoresis 450–453, 457
 - microneedles 450, 455–456
 - needle-free injector 456
 - puncturing 454
 - sonophoresis 450, 453–454
 - temperature 442, 445, 450, 454, 456
 - ultrasound 453–454, 457
 - permselective 451
 - P.L.E.A.S.E. (painless laser epidermal system) 456
 - radio-frequency ablation permeation enhancement 456
 - PowderJect needle-free system 456
 - Rogaine 447
 - scopolamine patch 173, 444, 448, 449, 457
 - soft enhancer of percutaneous absorption (SEPA) 447
 - solid microstructure transdermal system (sMTS) 455
 - sonophoresis permeability enhancement 453–454
 - SonoPrep ultrasound system 454
 - steady-state flux 444
 - Synera patch 450
- Transderm-Nitro 449
- Transderm-Scop 448
- transfersomes 450
- TriGrid electroporation system
 - drug-adhesive layer patch (Nito-Dur, Nicoderm CQ, Duragesic) layer patch (Deponit, Clonidine), **91**, 444, 448, 449
 - reservoir patch (Transderm-Nitro, Habitrol) 449
- trolamine salicylate 448
- ultrasound permeation enhancement 453–454
- transdermal patches 173, 195, 196, 443, 446, 448, 612, 735
- U.S.P. transdermal systems 444, 448
- Transfer of Ownership/Agents as Holders 633
- Transfersomes 450
- Translational science 711, 719
- Transmissible spongiform encephalopathy 338, 634
- Trastuzumab **101**
- Treatment IND 558, 559, 607–608
- Trehalose 85, 86, 166, 393, 425(a)
- Treprostinil sodium **101**
- Triacetin 28, 248, 269(a), 279, 296(a), 461(a), 470
- Triaminic 172
- Triamterene 51
- Tributyl citrate (TBC) 248
- Tricalcium phosphate **280**
- Triethyl citrate (TEC) 248, 296(a), 466
- Trifluoroacetic acid (TFA) 175
- TriGrid electroporation system 453
- Trimethoprim and sulfadiazine mixture **101**
- Trolamine salicylate 448
- Trovafloxacin mesylate **101**, 547(a)
- TRP, *see* Tamper-resistant packaging
- True density 108, 113, **221**, 226, 234, 238, 302, 303, 339, 348, **371**
- True solutions 18, 298
- Turbohaler 347
- Trypsin 162, 175
- TSE, *see* Transmissible spongiform encephalopathy
- Tubocurarine chloride **101**
- Tubular glass 405
- Tungsten pins 406
- Type I DMF 629
- Type I error, α , 131, 132

- Type II DMF
 drug intermediates, substances, and material used in their preparation 627, 629
 drug product 627, 629
- Type II error, β , 131
- Type III: packaging material 627, 629–630
- Type IV: excipient, colorant, flavor, essence, or material used in their preparation 627, 630
- Type of drug master files 627–628
 Type I 627, 629
 Type II 627, 629–631
 Type III 627, 629–631
 Type IV 627, 630, 631
 Type V 630
 Type V: other 627, 630
- Types of analytical procedure
 alternate analytical procedure 679
 regulatory analytical procedure 679
 stability-indicating assays 31, 220, 299, 338, 679, 689
 to be validated 679
- Types of clinical trials
 diagnostic trials 557
 prevention trials 556
 quality-of-life trials 557
 screening trials 557
 treatment trials 556
- Types of INDs
 emergency IND 559
 investigator IND 558–559
 in vitro–in vivo correlation 465–466
 treatment IND 559
- U**
- U.S. v. Johnson*, the Supreme Court ruled (in 1911) 477
- Ultane 612
- Ultrafine particle dispersions 298
- Ultrasonic nebulizers 341, 342
- Ultrasound permeation enhancement 453–454
- UNAIDS, *see* Joint United Nations Programme on HIV
- Unilamellar vesicles (LUV) 176, 316, 317
- United States Department of Agriculture. 519(a)
- United States Drug Enforcement Agency (United States) 513
- United States National Center for Toxicological Research (United States) 479, 516
- United States Pharmacopeia (U.S.P.)—National Formulary (N.F.) 46, 217, 338, 526, 542(a), 627, 673, 674
- United States Pharmacopeia Convention 538
- Unmet medical needs 606, 616
- Untitled letter 622
- Up-conversion nanoparticles 116
- UR, *see* User requirement
- Urapidil **101**
- Ursodeoxycholic acid **101**
- URS, *see* User required specification
- Use of approved components, drug product containers, and closures [Sec. 211.86] 489, 522(a)
- Use of vendor documentation 652
- User required specification 665
- User requirement 648, 651, 654–656, 676
- U.S.P. Biological Reactivity Tests 356, 406, 629
- U.S.P. dosage form nomenclature 191, 201(a), 209(a), 369
- U.S.P. Good Compounding Practices <1075>, 527–532, 540
- U.S.P. packaging fabrication materials and closure types 196, 213 (a), **249**
- U.S.P. packaging nomenclature 196, 212(a)–213(a), **249**
- U.S.P. particulate requirements for injectables 379
- U.S.P. Pharmaceutical <795>, 526
- U.S.P. Pharmaceutical Compounding–Nonsterile <797>, 526, 528, 530
- U.S.P. Pharmaceutical Compounding–Sterile Preparations 526, 528, 530
- U.S.P. Stability Considerations in dispensing practice <1191>, 526, 528
- U.S.P. water monographs
 pure steam **378**
 purified water **378**
 water for injection **378**, 379
 sterile water for injection **378**
- Utilities Commissioning 650
- V**
- Vaccine enhancement patch 456
- Vaccines 114, 166–169, **169**, 309, 370, 403, 444, 453, 455–457, 477, 480, 556, 575, 584, 607, 615, 618, 621, 624, 636, 643, 648, 700, 707, 709, 721, 722, 735, 739(a), 753
- Vaginal suppositories 210(a), 322
- Valid biomarker 708, 714, 715
- Validate analytical methodology 590
- Validation master plan, *see* VMP
- Validation of analytical procedures
 method validation 679–680
 other validation considerations 680
 revalidation 680
 types of analytical procedures 679
 types of analytical procedures to be validated 679–680
 validation protocols 679–680
- Validation team 665
- Valsartan 25–27, 51, **101**
- Valproate sodium **101**
- Vancomycin hydrochloride **101**
- Vaporization efficiency **249**
- Variance 49, 111, 130–132, 134–139, 145, 223, 232, 238, 291, 688
- V-blender 136, 194, 231, 231, 233, **233**, 236, 283
- VCPR, *see* Veterinarian–client–patient relationship
- Vectors 167, 174, 298, 304, 308–309, 578(a)
- Velocity 69, 70, 109, 111, **112**, 129, 139, 140, 231, 240, 242, 300, 302, 306, 323, 336, 337, **340**, 341, 344, 348, 381, 402, 456, 552(a), 553(a)
- Venlafaxine **101**
- Ventilation, air filtration, air heating and cooling [Sec. 211.46] 487, 520(a)
- Ventolin HFA 346
- Verapamil 124, 171, 468, 471
- Verification 373, 490, 501, 506–508, 514, 533, 537, 568, 647, 650, 652, 653, 655, 656, 658, 663–665, 677, 678, 681, 690(a), 715, 734, 747(a), 749(a)
- Veterinarian–client–patient relationship 541
- Veterinary compounding pharmacy 525, 537, 538

Veterinary International Conference on Harmonization
 International Cooperation on Harmonization of Technical 484,
 519(a)
 Requirements for Registration of Veterinary Products 484
 Veterinary Master Files 754, 755
 VGDS, *see* Voluntary genomic data submission
 Viable aerobic count 326
 ViaDerm RF system 456
 Vibrating mesh technology (VMT) 342
 VICH, *see* Veterinary International Conference on Harmonization
 Vinorelbine tartrate **101**
 Viscoelasticity 69, 72–74, 157
 Viscosity
 complex 73
 Cross model 73
 dynamic (η') 72, 73
 effect of ground-state 72, 74
 effect of pressure 57, 69, 241, 355, 404, 428
 internal friction 69
 rigid 72
 temperature 8, 13, 16, 29, 33, 58, 69, 70, 81, 170, 236, 241, 305, 306,
 310, 316, 320, 327, 342, 353, 384, 385, 389, 390, 404, 431, 445
 viscosity-inducing agents/viscosity enhancers 352, 353, 430, 464
 viscous modulus 72
 viscous (loss) modulus 72
 Vitamin A 51
 Vitamin and mineral supplement 172, 740
 Vitamin K1, **101**
 Vitravene intravitreal injection 436
 Vitrasert 436
 Vitreous humor 426(a), 428
 VMP (validation master plan) 648, 655, 665
 Voigt unit 72
 Volume-equivalent diameter 109
 Voluntary genomic data submission 708, 716(a)
 Vortex 228, 247, 307, 676

W

Waiver of Prescription Drug User Fee Act 612
 Warehousing procedures [Sec. 211.142] 493, 523(a)
 Washing and toilet facilities [Sec. 211.52] 487, 505, 520(a)
 Water (U.S.P.)
 pure steam **378**
 purified water 34, 39, 70, **378**, 393, **431**, 441(a), 448, 648, 649
 sterile water for injection **96**, **98**, **101**, **378**, 528, 533
 Water for injection **93**, **96**, **98**, **101**, **374**, **378**, 379, 416(a),
 441(a), 528, 533, 648, 649
 Water glass 405
 Water of hydration 37, 239
 Water substitute concept 393

Water vapor
 pressure–temperature profile 399
 transmission rate 251, 252
 Water-in-oil (W/O) emulsion 201(a), 209(a), 310, 314, 331, 386, 416(a)
 WEDD (wearable electronic disposable drug delivery) 453
 Weights and measures 9
 Weight size distribution 124
 Wet bulb 240, 241, **249**
 temperature 240, 241, **249**
 Wet extrusion 218, **219**, 234
 Wet granulation 15, 47, 108, 129, 190, **216**, 217–218, **219**, 223,
 225–228, 230, 233–236, 240, 242, 255, 256, 267(a), 283, 466,
 467, 468
 Wet granulation binders 223, 267(a)
 Wetting agents 20, 35, **222**, 224, 272(a), 276, 277, 304, 307, 384, 430,
 431, 441(a)
 Wetting time 138, 156
 WHO, *see* World Health Organization
 Williams–Landell–Ferry (WLF) 81
 Withdrawal time 532
 Work done by the mixer 307
 Work hardening 228, 237, 238
 Work of adhesion 54, 55
 Work of an isothermal expansion of an ideal gas 17
 Work of cohesion 54, 55
 World Health Organization 483, 502
 Worldwide regulatory agencies 477–484
 Written prescription drug interaction guidelines 528
 Written procedures; deviations [Sec. 211.100] 489–490,
 521(a)

X

Xcelodose 274
 Xopenax HFA 346
 X-ray diffraction 14, 15, 17, 21, 22, 31, 157, 239, 392

y

Yield value 71, 426(a)

z

Zero-shear rate viscosity 73
 Zeroth law of thermodynamics 11–12, 17
 Zeta potential 57, 116, 157, 301–302
 electric double layer 116, 301
 Zidovudine 605
 Zolmitriptan 172
 Zolpidem oral spray 353
 Zolpimist 353
 Zonisamide **101**
 Z values 400, 401, 416(a)